全文获取类型
收费全文 | 241篇 |
免费 | 16篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 14篇 |
妇产科学 | 7篇 |
基础医学 | 17篇 |
口腔科学 | 7篇 |
临床医学 | 35篇 |
内科学 | 71篇 |
皮肤病学 | 10篇 |
神经病学 | 4篇 |
特种医学 | 3篇 |
外科学 | 41篇 |
预防医学 | 21篇 |
药学 | 8篇 |
中国医学 | 1篇 |
肿瘤学 | 19篇 |
出版年
2023年 | 5篇 |
2022年 | 10篇 |
2021年 | 8篇 |
2020年 | 8篇 |
2019年 | 19篇 |
2018年 | 12篇 |
2017年 | 8篇 |
2016年 | 10篇 |
2015年 | 14篇 |
2014年 | 17篇 |
2013年 | 19篇 |
2012年 | 22篇 |
2011年 | 18篇 |
2010年 | 13篇 |
2009年 | 8篇 |
2008年 | 19篇 |
2007年 | 16篇 |
2006年 | 12篇 |
2005年 | 9篇 |
2004年 | 5篇 |
2003年 | 3篇 |
2002年 | 2篇 |
2001年 | 1篇 |
1998年 | 1篇 |
排序方式: 共有259条查询结果,搜索用时 15 毫秒
31.
George Dimopoulos Despoina Koulenti Suzanne L. Parker Jason A. Roberts Kostoula Arvaniti Garyphalia Poulakou 《Expert review of anti-infective therapy》2019,17(3):201-210
Introduction: The intravenous (IV) formulation of fosfomycin has been re-introduced in clinical practice mainly to overcome treatment failures against multidrug-resistant (MDR) bacteria. Appropriate dosing schedules of the IV formulation have not yet been established.Areas covered: The mechanism of action and resistance development, commercial IV formulations, pharmacokinetic/pharmacodynamic (PK/PD) properties, IV dosing regimens for the treatment of MDR infections along with efficacy and safety issues were reviewed. Data regarding specific MDR pathogens, daily doses and patients’ outcomes, gaps in the current literature, and in progress research agenda are presented.Expert opinion: The doses of fosfomycin IV range between 12 and 24 grams/day depending on the severity of infection. The efficacy and safety of the commonly administered doses have been shown mainly in observational non-comparative trials. The optimal dose ensuring maximal efficacy with minimal toxicity along with the most appropriate co-administered antibiotic(s) need further evaluation. The pharmacokinetic/pharmacodynamic parameter associated with maximum efficacy has not yet been established, although, the ratio of the area under the concentration-time curve (AUC) for the free unbound fraction of fosfomycin versus the MIC (fAUC/MIC) may be linked to optimal treatment. RCTs and other comparative studies are underway to address gaps of knowledge in adult patients and neonates. 相似文献
32.
Maria Mavroudi Despoina Papakosta Theodore Kontakiotis Kaliopi Domvri George Kalamaras Vasiliki Zarogoulidou Paul Zarogoulidis Paschalina Latka Haidong Huang Wolfgang Hohenforst-Schmidt Konstantinos Zarogoulidis 《Sleep & breathing》2018,22(2):393-400
Background
Interstitial lung diseases (ILD) are chronic and restrictive lung diseases with poor survival and quality of life. The aim of this study was to investigate the frequency of sleep disorders in idiopathic pulmonary fibrosis (IPF) and sarcoidosis and to assess patients’ quality of life in relation to these disorders.Methods
Forty patients, 19 with IPF, and 21 with sarcoidosis stage II/III were included. They were compared with 15 healthy subjects. All patients performed all-night polysomnography (PSG) and completed the Epworth, Berlin, and Stop-Bang questionnaires. In order to evaluate the quality of life, all patients completed the Short-Form 36 (SF-36) questionnaire.Results
Of the IPF patients, 68% were diagnosed with mild obstructive sleep apnea (OSA), 5.2% with moderate to severe, 5.2% with severe OSA, and 21% with no OSA. Of patients with sarcoidosis, 52.4% were diagnosed with mild OSA and 4.8% with moderate severity OSA. The remaining 42.8% did not have OSA. The health-related quality of life in both patients with IPF and patients with sarcoidosis was impaired especially in the domains concerning physical health and the level of independence, compared to the control group.Conclusions
In this sample of patients with IPF and sarcoidosis, obstructive sleep apnea is common at least in a mild degree of severity. The SF-36 questionnaire may be a useful tool for the evaluation of the quality of life in these patients.33.
34.
35.
Despoina Papadopoulou Argyro Fassoulaki Christos Tsoulas Ioanna Siafaka Athina Vadalouca 《Clinical rheumatology》2016,35(3):573-586
Fibromyalgia is characterized by widespread pain, sleep problems, fatigue, functional impairment, psychological distress, and cognitive dysfunction. The objective of this meta-analysis is to synthesize the available data on the effectiveness of pharmacological and non-pharmacological interventions across all domains included in the Outcome Measures in Rheumatology Clinical Trials (OMERACT-10) fibromyalgia response definitions, and to examine response based on these definitions. We searched Cochrane, PubMed, Scopus, and the reference lists of articles for randomized controlled trials of any drug formulation or non-pharmacological intervention used for fibromyalgia treatment. We extracted efficacy data regarding pain, sleep, physical function, fatigue, anxiety, depression, and cognition. The available data were insufficient to draw definite conclusions regarding response. Indirect evidence indicates that it may be expected with the use of serotonin noradrenaline reuptake inhibitors (SNRIs), noradrenaline reuptake inhibitors (NRIs), and multidisciplinary treatment. 相似文献
36.
37.
Karadimas EJ Nicolson T Kakagia DD Matthews SJ Richards PJ Giannoudis PV 《International orthopaedics》2011,35(9):1381-1390
Purpose
The purpose of this study was to evaluate the relation between pelvic fracture patterns and the angiographic findings, and to assess the effectiveness of the embolisation. 相似文献38.
39.
40.